Infosint, S.A. v. H. Lundbeck A/S

718 F. Supp. 2d 445, 2010 U.S. Dist. LEXIS 60104, 2010 WL 2465432
CourtDistrict Court, S.D. New York
DecidedJune 17, 2010
Docket06 Civ. 2869(LAK)
StatusPublished
Cited by1 cases

This text of 718 F. Supp. 2d 445 (Infosint, S.A. v. H. Lundbeck A/S) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Infosint, S.A. v. H. Lundbeck A/S, 718 F. Supp. 2d 445, 2010 U.S. Dist. LEXIS 60104, 2010 WL 2465432 (S.D.N.Y. 2010).

Opinion

MEMORANDUM OPINION

LEWIS A. KAPLAN, District Judge.

This is an action for infringement of a patent for the synthesis of a chemical compound used by defendants in their manufacture of the antidepressant drug citalopram. The case was tried to a jury, which found that defendants had infringed the patent and awarded plaintiff fifteen million dollars in damages. The matter is before the Court on defendants’ post-verdict motion for judgment as a matter of law that plaintiffs patent is invalid as obvious.

Background

Plaintiff Infosint, S.A. (“Infosint”) owns the patent here at issue, U.S. Patent No. 6,458,973 (the “'973 Patent”), which claims an improved process for making the compound 5-carboxyphthalide, which is used as an intermediate in the synthesis of citalopram and another antidepressant drug, escitalopram. 1

In general terms, the claimed process involves adding terephthalic acid to fuming sulfuric acid containing at least twenty percent sulfur trioxide, S03. Fuming sulfuric acid, also known as oleum, 2 is a mixture of sulfuric acid, H2S04, and sulfur trioxide. Next, formaldehyde or a formaldehyde precursor is added to the mixture, which is heated at 120-145 C. The resulting 5-earboxyphthalide then is isolated from the solution. 3

Defendants, H. Lundbeck A/S and subsidiary Lundbeck, Inc. (collectively “Lundbeck”), as well as Forest Laboratories, Inc., and Forest Pharmaceuticals, Inc. (collectively “Forest”), manufacture, market, and sell citalopram and escitalopram. 4 Lundbeck synthesizes 5-carboxyphthalide and manufactures citalopram and escitalopram at facilities located outside of the United States. Forest markets and sells these pharmaceuticals in the United States under the trademarks Celexa and Lexapro, respectively. 5

The Dispute

Infosint claimed that Lundbeck used 5-carboxyphthalide made according to the process described in the '973 Patent as an intermediate in its production of citalopram and escitalopram, that Forest infringed by importing into and offering for sale in the United States citalopram and escitalopram products, and that Lundbeck induced Forest to do so.

Defendants contended that the '973 Patent does not cover the processes used by Lundbeck to make citalopram or escitalo *447 pram. They contended also that the patent is invalid on the ground that the claimed process was anticipated by the prior art and obvious to one of ordinary skill in art at the time it was invented.

The case was tried to a jury for three weeks in September and October 2009.

The Verdict

At the close of the evidence, defendants moved for judgment as a matter of law “on the invalidity defenses” pursuant to Federal Rule of Civil Procedure 50(a). 6 The Court reserved decision 7 and allowed the case to go to the jury. On October 15, 2009, the jury returned a verdict for Infosint. It found that the claimed process was neither anticipated nor obvious. It found also that defendants had infringed the '973 Patent and awarded Infosint what it deemed to be a reasonable royalty, viz. $15 million. 8 Defendants now move for judgment as a matter of law that the '973 Patent is invalid as obvious.

Discussion

A. Legal Standard

A motion for judgment as a matter of law will be granted “only when, considering the evidence in the light most favorable to the non-moving party and drawing all reasonable evidentiary inferences in that party’s favor, there was ‘no legally sufficient evidentiary basis for a reasonable jury to find’ in favor of the non-moving party.” 9 In deciding the motion, a court “cannot assess the weight of conflicting evidence, pass on the credibility of the witnesses, or substitute its judgment for that of the jury.” 10

The ultimate judgment of obviousness is a legal determination. 11 “The moving party is entitled to [judgment as a matter of law] when the court is convinced: (1) that reasonable persons could not in light of th[e] evidence have found the facts necessary to support the jury’s verdict; or (2) that the facts properly found cannot in law support that verdict.... Thus the trial judge engages in a two step process ... :(1) determine what facts are supported by substantial evidence; and (2) determine whether those facts support the legal conclusion necessarily drawn by the jury en-route [sic ] to its verdict.” 12

B. Analysis

Defendants contend that Claim 24 of the '973 Patent is obvious as a matter of law on the ground that each of its limitations was disclosed by prior art. Infosint *448 responds that defendants do not meet their burden of demonstrating obviousness because there was substantial evidence that the prior art taught away from the claimed process.

The '973 Patent claims in relevant part:
“1. A process for the preparation of 5-carboxyphthalide ... which comprises adding formaldehyde and terephthalic acid ... to fuming sulfuric acid containing at least 20% of S03, heating the mixture at 120-145 C. and isolating the 5-carboxyphthalide thus obtained.
“21. A process for the synthesis of citalopram, in which a process for the synthesis of 5-carboxyphthalide according to claim 1 is contained.
“23. A process for the preparation of 5-carboxyphthalide ... which comprises adding formaldehyde (or a formaldehyde precursor) and terephthalic acid ... to fuming sulfuric acid containing at least 20% of S03, heating the mixture at 120-145 C. and isolating the 5-carboxyphthalide thus obtained, wherein the process is conducted in an open, non-pressurized reactor.
“24. A process for the synthesis of citalopram, comprising the process for the synthesis of 5-carboxyphthalide according to claim 23.” 13

This Court on a motion for summary judgment prior to trial held Claims 1 and 21 of the '973 Patent invalid as obvious. 14 The remaining asserted claim of the '973 Patent, Claim 24, differs from invalidated Claim 21 only with respect to the “open, non-pressurized reactor” limitation. 15

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
718 F. Supp. 2d 445, 2010 U.S. Dist. LEXIS 60104, 2010 WL 2465432, Counsel Stack Legal Research, https://law.counselstack.com/opinion/infosint-sa-v-h-lundbeck-as-nysd-2010.